Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 234

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

A randomized trial of mesenchymal stem cells in multiple system atrophy

Open access
Lee, Phil Hyu, Lee, Ji E., Kim, Han‐Soo, Song, Sook K., Lee, Hye Sun, Nam, Hyo Suk, Cheong, June‐Won, Jeong, Yong, Park, Hae‐Jeong, Kim, Dong Joon, Nam, Chung Mo, Lee, Jong Doo, Kim, Hyun Ok, Sohn, Young H.·2012·Annals of Neurology

Abstract

Objective: Neuroprotective or regenerative strategies are invaluable in multiple system atrophy (MSA) due to its rapid progression with fatal prognosis. We evaluated the efficacy of autologous mesenchymal stem cells (MSC) in patients with MSA‐cerebellar type (MSA‐C). Methods: Thirty‐three patients with probable MSA‐C and baseline unified MSA rating scale (UMSARS) scores ranging from 30 to 50 were randomly assigned to receive MSC (4 × 10 7 /injection) via intra‐arterial and intravenous routes or placebo. The primary outcome was change in the total UMSARS scores from baseline throughout a 360‐day follow‐up period between groups. Secondary outcomes were changes in the UMSARS part II scores, cerebral glucose metabolism, gray matter density, and cognitive performance over a 360‐day period. Results: The mixed model analysis of neurological deficits revealed a significant interaction effect between treatment group and time, suggesting that the MSC group had a smaller increase in total and part II UMSARS scores compared with the placebo group ( p = 0.047 and p = 0.008, respectively). Cerebral glucose metabolism and gray matter density at 360 days relative to the baseline were more extensively decreased in the cerebellum and the cerebral cortical areas, along with greater deterioration of frontal cognition in the placebo group compared with the MSC group. We found no serious adverse effects that were directly related to MSC treatment. However, intra‐arterial infusion resulted in small ischemic lesions on magnetic resonance imaging. Interpretation: MSC therapy could delay the progression of neurological deficits in patients with MSA‐C, suggesting the potential of MSC therapy as a treatment candidate of MSA. ANN NEUROL 2012;72:32–40

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ana.23612

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 234

Metadata

Authors
Lee, P. H., Lee, J. E., Kim, H., Song, S. K., Lee, H. S., Nam, H. S., Cheong, J., Jeong, Y., Park, H., Kim, D. J., Nam, C. M., Lee, J. D., Kim, H. O., & Sohn, Y. H.
Venue
Annals of Neurology
Publisher
Wiley
Published
2012-07
Volume
72
Issue
1
Pages
32-40
ISSN
  • 0364-5134 (ISSN-L)
  • 1531-8249
OpenAlex
W1991849900
Cited by
234
References
2
FWCI
9.99
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized trial of mesenchymal stem cells in multiple system atrophy. https://app.cochat.ai/papers/10.1002/ana.23612
The paper
Lee, P. H., Lee, J. E., Kim, H., Song, S. K., Lee, H. S., Nam, H. S., Cheong, J., Jeong, Y., Park, H., Kim, D. J., Nam, C. M., Lee, J. D., Kim, H. O., & Sohn, Y. H. (2012). A randomized trial of mesenchymal stem cells in multiple system atrophy. Annals of Neurology. https://doi.org/10.1002/ana.23612

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.